Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Anthera Pharmaceuticals Launches With a Proven Leadership Team and Significant Series A Funding

By Pharmaceutical Processing | April 26, 2005

SAN FRANCISCO — Anthera Pharmaceuticals, Inc, a private start-up pharmaceutical company specializing in serious respiratory and inflammatory diseases, recently announced it has completed its Series A Preferred financing and is moving forward under a proven leadership team. The new company will be lead by Paul Truex in the role of President and Chief Executive Officer, who has extensive experience building successful companies, most recently Peninsula Pharmaceuticals. Mr. Truex has already enlisted a highly capable team to serve with him on the Board of Directors, including Lowell E. Sears of Sears Capital Management, who will lead the board as Chairman.

“Paul was the driving force behind the success of Peninsula Pharmaceuticals, which has been acquired by the Ortho-McNeil Pharmaceuticals division of Johnson & Johnson, and his leadership built the company from its inception,” said Mr. Sears. “I am very excited to back the creation of a new company around Paul’s capabilities and demonstrated accomplishment in executing an in-licensing strategy to build a specialty pharmaceutical company.”

“Our first funding efforts met our goals and we are gratified by the confidence that our initial investors have shown in our vision. Our strategy to in-license compounds presents a great opportunity to jump start the development process with a viable product,” said Paul F. Truex, President and Chief Executive Officer. “Anthera will seek to bring products to market in areas that have the capacity for new compounds and better therapeutic options, including cystic fibrosis, COPD, asthma and acute lung injury. We are already negotiating multiple product opportunities and hope to be able to announce the acquisition of one or more of these in the near future.”

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Wyzo
Wyzo high-speed pick-and-place sidebot wins design awards
Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards